Corbus aligns with FDA on pivotal path for CRB-701
FDA alignment derisks the most common reason Phase 3 trials fail. What Corbus does with the compressed calendar is the whole equity story.
Three years of durable vision in the MeiraGTx long-term follow-up
36-month ARVO readout confirms durability. Rerating to generalist biotech flows needs a second catalyst. What would change the call.
Clearmind's AUD Phase 1/2a hits its primary — with a catch
First-cohort biomarker hit for CMND-100 in alcohol use disorder. Three signals to watch through the next two cohorts.
Theriva's AACR data isn't the story. The cash runway is.
Phase 2b oncolytic-virus data at AACR. But the balance sheet is what actually moves the equity — cash runway analysis and three financing paths.
The boring biotech thesis: Biofrontera is actually selling things
Ameluz revenue growing high-teens. OpEx flat. Sales-force buildout finally scaling. The textbook commercial-stage inflection — just without the story-stock drama.
Jaguar Health pivots to dogs. Whether it matters depends on the label.
Crofelemer's canine CID trial is the first real platform-extension shot. Human vs. veterinary economics are not the same model.